SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
- Dytfeld, Dominik
- Radocha, Jakub
- Hajek, Roman
- Cengiz-Seval, Guldane
- Berkac, Meral
- Coriu, Daniel
- Derman, Benjamin
- Jakubowiak, Andrzej
- Peceliunas, Valdas
- Mikala, Gabor
- Bołkun, Łukasz
- Hawrylecka, Dorota
- Grosicki, Sebastian
- Tyczyńska, Agata
- Zaucha, Jan Maciej
- Knopińska, Wanda
- Semeńczuk, Grażyna
- Morawska, Marta
- Giannopoulos, Krzysztof
- Puła, Anna
- Rymko, Marcin
- Charliński, Grzegorz
- Szeremet, Agnieszka
- Kalicińska, Elżbieta
- Usnarska, Lidia
- Wróbel, Tomasz
- Jamroziak, Krzysztof
- Druzd-Sitek, Agnieszka
- Romejko Jarosińska, Joanna
- Sawicki, Waldemar
- Waszczuk-Gajda, Anna
- Juda, Adrian
- Hus, Marek
- Gil, Lidia
DOIAbstract
Introduction: Despite several studies, the impact of coronavirus disease 2019 on patients with multiple myeloma remains uncertain. Material and methods: We performed a survey that covered the period of the first and second waves of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 23 centers inseven countries. Out of 352 patients with myeloma and SARS-CoV-2, 23% died. Results/Conclusions: Logistic regression showed a lower risk of death among patients treated with proteasome inhibitor and a higher risk of death for those who had a severe or a very severe course of disease
Add to ORKG